我们是谁
我们想做什么
Unique oral non degradative MG assets
Un-targetable targets
Blockbuster
AI-driven process
to Empower medicine development and delivery
for Simple , effective and safe medicines.
We started on LinGang Biobay in Shanghai in 2024. We create new process to screening blockbuseter potential unmet needs globally with oral non degradative MG platform approch. Reaching antibody like potency in unique Indication patient pool.
The ultimate goal is for better experiences for patients to be able to get simple, effective and safe medicines for their illness and potentially change the treatment paradigms, to contribute to reduce the pain, financial burden on medical for both indiviuals and the society.
我们在做什么
2025
Oral non degradative MG Platform
AI driven deepOcean nature compounds discovery and data base with NSFC funding projects.
Discover deepOcean like oral non degradative MG compunds for Anti-coagulation and bleeding diseases: Ischemic stroke,atrial fibrillation,Hemophilia A/B; Paroxysmal nocturnal hemoglobinuria; with Targets: FXI ; TFPI(Kunitz-2), Complement C5
2026
Partnership with Gluetacs in Shanghai, co-develop next-gen oral non degradative MG assets in autoimmune diseases.
Partnership with Amgen, GSK colleagues in Boston, co-develop unmet needs in global.
Pipeline & Assets
IL4Ra-MGI Oral Once daily/ Once weekly
Discovery stage
Atopic dermatitis; Asthma; Chronic rhinosinusitis with nasal polyps;Eosinophilic esophagitis; Prurigo nodularis;
FXI/FXIa-MGI Oral Once daily/ Once weekly
Discovery Stage
Secondary Stroke Prevention, SSP；
我们的伙伴们
Business team: Ren Chuanyun/ Transection background with MNC, lead disruptive innovation in Proptech Assets management with 35% of top 500 MNC
AI team:
Liu Ming /IT master of Tianjing University/Huawei /Big Data
Bio team:
Prof.WU wenhui/Director of Pharmcy Shanghai Ocean University/Pujiang Scholar/Shanghai Pharmaceutical Association VP；Zhang haixing BioPharma PHD of Shanghai Ocean University etc
Cheimcal team:
Zeng Fanyun/Chem master of Tianjing University/Chempartner/Wuxi Chemistry
Advisors:
Yang XiaoBao，CEO of Gluetac/GSK, JiangBiao Academician of the Chinese Academy of Sciences (CAS);
Chen Liangbiao，University of Illinois Urbana-Champaign (UIUC) PHD,NIH Postdoctor,Hundred of CAS, Allowance of the State Council
联系我们
Maxios Therapeutics
Email: ceo@maxiostx.com
Address: Building 4, No. 218 Haiji 6th Road, Pudong, Shanghai, China
Postal Code: 201308
